Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer pill keep working outside the lab? a Real-World test begins

NCT ID NCT04553926

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study monitors the safety and effectiveness of the drug olaparib (Lynparza) in people with ovarian, breast, prostate, or pancreatic cancer who are prescribed it as part of routine care in South Korea. Researchers will track side effects and how long the cancer stays under control without requiring extra study visits. The goal is to see how well the drug performs in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a PARP inhibitor drug called olaparib (Lynparza)
What this could lead to
If successful, this study could confirm that olaparib works safely in everyday clinical practice for several cancers.
What could go wrong
This is an observational post-marketing study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by how doctors choose treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

661 people

The number who actually took part.

Started

Feb 2021

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

On active study drug treatment according to the approved local label.

Ages

19 to 150 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Eligible for the study drug treatment according to the approved label in South Korea 2. Provision of signed and dated written informed consent by the patient or legally acceptable representative Exclusion Criteria: 1. History of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug 2. Prior exposure to any Polyadenosine 5'diphosphoribose polymerase (PARP) inhibitors, including the study drug 3. Pregnant and/or breast feeding 4. Current participation in any interventional trial 5. Other off-label indications according to the approved label

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm malignant pancreatic neoplasm ovarian cancer pancreatic neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Ovarian cancer Pancreatic cancer Prostate cancer

Contacts and locations

Locations

  • Research Site

    Ansan, South Korea

  • Research Site

    Bucheon-si, South Korea

  • Research Site

    Busan, South Korea

  • Research Site

    Changwon, South Korea

  • Research Site

    Daegu, South Korea

  • Research Site

    Daejeon, South Korea

  • Research Site

    Goyang, South Korea

  • Research Site

    Gunpo, South Korea

  • Research Site

    Hwaseong, South Korea

  • Research Site

    Ilsan, South Korea

  • Research Site

    Incheon, South Korea

  • Research Site

    Jeonju, South Korea

  • Research Site

    Seongnam, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Suwon, South Korea

  • Research Site

    Uijeongbu-si, South Korea

  • Research Site

    Yangsan, South Korea

  • Research Site

    Yongin, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.